tHEORetically speaking HealthEconomics.com

In this episode of tHEORetically speaking, Dr. Joseph Zabinksi, VP and Head of Commercial Strategy and AI at OM1, explains how AI-powered digital phenotyping can enhance our understanding of patients' experiences and inform access, treatment, and condition management.Real-world data provides an opportunity to understand what happens to patients, but there are limitations to the insights we can generate using traditional analysis techniques alone. At OM1, our PhenOM technology uses AI to isola...

In this episode of tHEORetically Speaking, join Kelly Lipman, Heather Dickerson, and Ryan Murphy from ICON, who answer questions from a recent webinar on the dynamic landscape of clinical outcomes assessments, examining their historical significance, current uses and best practices, and making a case for greater standardization in their implementation.For more information, to watch the webinar, or access other resources, click here.

In this episode of tHEORetically Speaking, join Dr. Rosemary Jose, Dr. Sonja Kroep, and Nick Halfpenny from OPEN Health, Dr. Ansgar Hebborn from Roche, and James Ryan from AstraZeneca, who answer questions from a recent webinar on several policy aspects regarding the current challenges and implications of the EU Health Technology Assessment (HTA) regulation.For more information, to watch the webinar, or access other resources, click here.

In this episode of tHEORetically Speaking, join Dr. Pamela Landsman-Blumberg, Amanda O’Hora, and Ajay Keshava from Magnolia Market Access, who answer questions from a recent webinar on how early stage planning taking into account commercial production, logistics, reimbursement, and health inequities can lead to successful approvals and market adoption.For more information, to watch the webinar, or access other resources, click here.

In this episode of tHEORetically Speaking, join Drs. Megan Gower and Edward Chou from Takeda, and Richard Tsai, MS from Inspire, who answer questions from a recent webinar on the challenges and solutions for generating patient-centered real-world evidence (RWE) in the context of rare diseases, to support clinical development through commercial post-approval.For more information, to watch the webinar, or access other resources, click here.

In this episode of tHEORetically Speaking, join Drs. Javier Cid, Nahila Justo, and Delphine Saragoussi from Evidera and PPD, who answer questions from a recent webinar on why strong connections with registry groups and stakeholder populations are important for generating relevant real-world evidence to advance treatments.For more information, to watch the webinar, or access other resources, click here.